阿洛普林醇可以预防肝硬化相关的并发症:四重盲目的安慰剂对照试验
Khadija A M Glal1, Sahar M El-Haggar1, Sherief M Abdel-Salam2
1Department of Clinical Pharmacy, Faculty of Pharmacy.
The American journal of medicine
|October 13, 2023
概括
阿洛普林醇显著降低了肝硬化并发症在肝脏衰竭的患者. 这项研究表明,阿洛普林醇是一种有前途的治疗方法,可以预防这些患者出现严重的健康问题.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
背景情况:
- 肝硬化并发症往往是致命的,肝脏不补偿的治疗选择有限.
- 探索新的治疗策略对于管理晚期肝病至关重要.
研究的目的:
- 研究艾洛普林醇在预防肝硬化和肝衰竭患者复发并发症复发中的有效性.
主要方法:
- 一项随机对照试验,涉及100名肝脏不补偿症患者.
- 患者每天接受阿洛普林300毫克或安慰剂,持续6个月.
- 主要终点:肝硬化相关并发症的发生率,包括,自发细菌性腹膜炎,水出血,肝综合征和肝脑病变.
主要成果:
- 阿洛普林醇可以将任何第一次并发症的相对风险降低56% (HR 0.44;P < .001).
- 显著的减少被观察到在明显的炎 (67%),自发的细菌性腹膜炎 (75%) 和肝综合征 (80%).
- 阿洛普林醇在多种关键性肝硬化并发症中显示出了统计学上显著的益处.
结论:
- 阿洛普林醇显著降低了整体肝硬化相关并发症的复发率.
- 阿洛普林醇显示出作为患有肝脏衰竭的患者治疗剂的前景.
- 潜在的机制包括减少细菌转移和炎症.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
519
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
519
Drugs for Treatment of Ulcerative Colitis in IBD
152
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
152
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
462
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
462
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
439
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
439
Peptic Ulcer Disease IV: Management
108
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
108
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
491
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
491


